Last reviewed · How we verify
NCT05129215: PORTLARS
Development and Validation of The Post-RT LARS Prediction Model (PORTLARS)
trial testing Questionnaire in Low Anterior Resection Syndrome in 901 participants. Completed in 31 October 2022.
31 October 2022
Quick facts
| Lead sponsor | Sixth Affiliated Hospital, Sun Yat-sen University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 901 |
| Start date | 6 March 2020 |
| Primary completion | 31 October 2022 |
| Estimated completion | 31 October 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Questionnaire
Conditions studied
- Low Anterior Resection Syndrome — all drugs for Low Anterior Resection Syndrome →
- Radiotherapy — all drugs for Radiotherapy →
- Rectal Cancer — all drugs for Rectal Cancer →
Sponsor
Sixth Affiliated Hospital, Sun Yat-sen University
Who can join
Eligibility, any sex, with Low Anterior Resection Syndrome or Radiotherapy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Bowel dysfunction is common after a restorative rectal cancer resection. Neoadjuvant radiotherapy is an influential factor that impairs bowel function and quality of life. However, almost half patients who have received primary surgery with preoperative radiotherapy are able to restore a good or moderate bowel function in the long term. This multicenter observational study aims to identify the risk factors of severe bowel dysfunction after rectal cancer resection and neoadjuvant radiotherapy, in accordance with the LARS score, and to build a model that predicts long-term major LARS in the early stage of follow-up. Development and validation cohorts are enrolled from tertiary hospitals in China.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Development and Validation of a Post-Radiotherapy Prediction Model for Bowel Dysfunction After Rectal Cancer Resection.
Qin Q, Huang B, Wu A, Gao J, et al · · 2023 · cited 15× · PMID 37625498 · DOI 10.1053/j.gastro.2023.08.022
Verify or expand the search:
- PubMed search for NCT05129215
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Questionnaire
Trials testing the same drug.
- NCT04466371 — Perceptions of Undergraduate Students and Teaching Staff on Online Teaching · suspended
- NCT07089953 — Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits: a Randomiz · NA · not yet recruiting
- NCT07418775 — Tumor Genomics, Individual Risk Factors, and External Drivers of Health on Health Outcomes for Patients With Meningioma · not yet recruiting
- NCT07226804 — Nanosecond Pulsed Field Ablation in the Management of Benign Thyroid Nodules · not yet recruiting
- NCT07532954 — The Impact Of A Patient Support Community On Patients With Neuroendocrine Cervical Cancer: NECC Peer Support · recruiting
Other recruiting trials for Low Anterior Resection Syndrome
Currently open trials in the same condition.
- NCT07537998 — Antegrade Intestinal Fluid Reinfusion for Prevention of Low Anterior Resection Syndrome After Low Anterior Resection: a · Phase 2, PHASE3 · recruiting
- NCT06424522 — A Bowel Management Program (Retrograde Rectal Enema) for the Treatment of Low Anterior Resection Syndrome in Rectal Canc · NA · recruiting
- NCT06758830 — Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. · Phase 2, PHASE3 · recruiting
- NCT06724198 — Bowel Dysfunction After Low Rectal Resection. An Pilot Study Using Psyllium Husk In Rectal Cancer Patients. · NA · active not recruiting
- NCT06222255 — The Safety and Efficacy of Transanal Irrigation in Patients With Sleep Disturbance From Low Anterior Resection Syndrome · NA · recruiting
Other Sixth Affiliated Hospital, Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07538284 — MInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES) · Phase 2, PHASE3 · not yet recruiting
- NCT07176182 — Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression · Phase 2 · not yet recruiting
- NCT07510191 — TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response · Phase 4 · recruiting
- NCT07344428 — Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease: A Randomized Trial · NA · not yet recruiting
- NCT07328958 — Effect of Titrated Administration of Ciprofol on Perioperative Hypotension in Elderly Patients Undergoing Laparoscopic A · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05129215 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sixth Affiliated Hospital, Sun Yat-sen University
- Last refreshed: 30 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05129215.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing